Analysts Highlight Vyvgart Expansion as Major Growth Driver for Argenx (ARGX)

The institution reported net per stock of $8.02, exceeding the projected $5.95. Revenue besides came successful somewhat supra expectations, totaling $1.29 cardinal vs $1.28 billion.

According to Oppenheimer, Vyvgart’s full revenues for the 4th fourth of 2025 totaled $1.29 billion, a 74% summation implicit the erstwhile year. Vyvgart’s important myositis readout successful the 3rd 4th whitethorn pave the way for an further 20,000-patient opportunity.

Additionally, connected February 26, BofA Securities maintained a Buy standing connected Argenx SE (NASDAQ:ARGX) and accrued its terms nonsubjective from $1,006 to $1,013. The steadfast ranked Argenx arsenic a apical prime and kept its Vyvgart income projection level compared to the 4th fourth of 2025 for the coming first-quarter 2026 earnings.

Argenx SE (NASDAQ:ARGX) is simply a Netherlands-based planetary biotechnology institution focused connected developing, manufacturing, and commercializing antibody-based therapies for terrible autoimmune diseases and cancers.

While we admit the imaginable of ARGX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey connected Google News.